BioCentury
ARTICLE | Clinical News

DCR-PH1: Phase I started

May 23, 2016 7:00 AM UTC

Dicerna began the open-label, dose-escalation, international Phase I DCR-PH1-101 trial to evaluate IV DCR-PH1 in patients ages >=12. DCR-PH1 uses lipid nanoparticle (LNP) delivery technology from Arbu...